Bayer Thrombosis Research Award
This award recognizes early-career researchers for their outstanding achievements in basic or clinical thrombosis research every two years.
What is the Bayer Thrombosis Research Award?
Every other year this award recognizes early-career researchers for their exceptional accomplishments in either basic or clinical thrombosis research. The award was established thanks to the generosity of the former Bayer scientists Dr. Frank Misselwitz, Dr. Dagmar Kubitza and Dr. Elizabeth Perzborn honored with the German Future Prize ("Deutscher Zukunftspreis des Bundespräsidenten") for their invention on the anticoagulant Xarelto®.
Who can be nominated?
- Outstanding early-career scientists working in a German-speaking country (Germany, Austria or Switzerland) or have completed significant parts of their scientific training in the German-speaking world
- Possess a proven track record of scientific excellence
Have completed their PhD or MD - Be younger than 38 years
- Demonstrate exceptional achievements in basic or clinical research related to thrombosis, particularly focusing on the diagnosis, prevention, and treatment of thromboembolic diseases, including epidemiology and health policy approaches
What is the process for nominations?
Self-nominations are not considered.
Candidates for the award are nominated by senior members of esteemed scientific institutions or by scientific leaders within Bayer's research and development.
Contact us if you want to be part of the nominating group.
What is the prize?
This recognition includes a prize of €30,000.
Who selects the winners of these awards?
The winners are selected by a panel of Bayer internal and external experts in the field.